NexEos Bio
Pre-clinicalThe NexEos Bio lead program (NDX33-o) is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).
Founded
2020
Focus
DiagnosticsSmall Molecules
About
The NexEos Bio lead program (NDX33-o) is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).
Funding History
1Total raised: $40M
Series A$40MFrazier Life SciencesMay 15, 2022
Company Info
TypePrivate
Founded2020
LocationSan Diego, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile